Viatris

Viatris. Viatris is a global healthcare company formed in November 2020 through the merger of Mylan and Pfizer's Upjohn business, creating one of the world's largest pharmaceutical enterprises by revenue. Headquartered in Canonsburg, Pennsylvania, the company operates in over 165 countries and territories, focusing on providing access to a broad portfolio of medicines. Its mission centers on empowering people worldwide to live healthier at every stage of life through the development, manufacturing, and distribution of its products.

History

The formation of Viatris was the result of a strategic combination between the established generic drug giant Mylan and the off-patent branded medicines division of Pfizer, known as Upjohn. This transaction, valued at approximately $12 billion, was announced in July 2019 and finalized in November 2020, receiving necessary approvals from global regulators including the U.S. Securities and Exchange Commission and the European Commission. The merger was designed to create a new company with enhanced scale, geographic reach, and a diversified portfolio to navigate the evolving pharmaceutical industry. Prior to the merger, Mylan had a long history dating back to 1961 and was known for products like the EpiPen, while the Upjohn legacy included historic brands originally developed by the Upjohn Company, which Pfizer had acquired in 2003.

Business operations

Viatris organizes its commercial activities into four key geographical segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. The company maintains a significant global manufacturing and supply chain footprint, with research and development facilities, and manufacturing sites spread across the Americas, Europe, and Asia. Its operational strategy emphasizes efficiency and reliability in supplying high-quality medicines, leveraging the combined infrastructure and expertise from its legacy companies. Key operational assets include a major global network for producing active pharmaceutical ingredients and finished dosage forms, ensuring a steady supply of essential products to markets worldwide, from the United States to India.

Products

The company's extensive portfolio encompasses hundreds of products across multiple therapeutic areas, including cardiovascular disease, dermatology, and central nervous system disorders. It markets a wide array of generic medicines, well-known branded products like Lipitor (atorvastatin) and Viagra (sildenafil), biosimilars such as Abevmy and Fulphila, and a range of over-the-counter drugs. Notable products also include complex generics and injectable medicines, which are critical in hospital settings. This diversified portfolio allows Viatris to serve patients, healthcare professionals, and payers across both developed economies and emerging markets, addressing needs in areas like infectious diseases and non-communicable diseases.

Corporate affairs

Viatris is led by Executive Chairman Robert J. Coury and Chief Executive Officer Scott A. Smith, with its board of directors comprising leaders with extensive experience in the healthcare and financial sectors. The company is publicly traded on the NASDAQ under the ticker symbol VTRS and is a constituent of the NASDAQ-100 index. It engages in various corporate social responsibility initiatives, focusing on expanding access to medicine, environmental sustainability, and ethical business practices. Viatris has also been involved in strategic divestitures, such as the sale of its biologics business to Incyte and its women's healthcare assets to Theramex, to optimize its portfolio and sharpen its strategic focus on core therapeutic areas.

Financial performance

As a newly formed entity, Viatris reported substantial pro forma revenue in its first full year, reflecting the combined sales of its legacy portfolios from Mylan and Upjohn. The company's financial strategy focuses on generating strong cash flow, which is allocated towards reducing debt from the merger, investing in growth initiatives, and returning capital to shareholders. Key financial metrics are closely watched by analysts from firms like Goldman Sachs and J.P. Morgan, with performance influenced by factors such as pricing dynamics in the United States, growth in emerging markets like China and India, and the successful integration of the merged operations. Its financial outlook is tied to the lifecycle management of its branded products and the continued expansion of its biosimilar and complex generic drug pipeline.